Subscribe to RSS
DOI: 10.1055/a-1216-4405
No Independent Association of Circulating Fetuin-A with Insulin Sensitivity in Young Women
Funding Information: German Center for Diabetes Research; Helmholtz Zentrum München; Klinikum der Universität MünchenAbstract
Animal data link high circulating fetuin-A to low insulin sensitivity and observational studies identify the hepatokine as a marker of future incident type 2 diabetes mellitus in humans. However, a recent, well-powered Mendelian randomization study finds no causal role. We therefore tested in a deeply-phenotyped human cohort if circulating fetuin-A correlates independently with insulin sensitivity and how it relates to the metabolic syndrome and ectopic fat deposition. We analyzed data from 290 young women with and without recent gestational diabetes mellitus. We found that circulating fetuin-A correlates inversely with insulin sensitivity in univariate analyses, but that this correlation is lost after adjustment for markers of the metabolic syndrome and of fatty liver. Additionally, we investigated which fat compartment associates most strongly with circulating fetuin-A. In whole body MRI data from a subcohort of 152 women, this was liver fat content. We conclude that high circulating fetuin-A occurs as part of the metabolic syndrome in young women and associates most strongly with liver fat content. Its close link to the metabolic syndrome may also cause the inverse correlation of circulating fetuin-A with insulin sensitivity as we found no independent association.
Key words
type 2 diabetes - metabolic syndrome - non-alcoholic fatty liver disease - mineral metabolismPublication History
Received: 20 January 2020
Accepted after revision: 08 July 2020
Article published online:
06 August 2020
© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Holt SG, Smith ER. Fetuin-A-containing calciprotein particles in mineral trafficking and vascular disease. Nephrol Dial Transplant 2016; 31: 1583-1587
- 2 Hennige AM, Staiger H, Wicke C. et al. Fetuin-A induces cytokine expression and suppresses adiponectin production. PloS one 2008; 3: e1765
- 3 Pal D, Dasgupta S, Kundu R. et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 2012; 18: 1279-1285
- 4 Srinivas PR, Deutsch DD, Mathews ST. et al. Recombinant human alpha 2-HS glycoprotein inhibits insulin-stimulated mitogenic pathway without affecting metabolic signalling in Chinese hamster ovary cells overexpressing the human insulin receptor. Cell Signal 1996; 8: 567-573
- 5 Stefan N, Haring HU. Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nat Med 2013; 19: 394-395
- 6 Stefan N, Hennige AM, Staiger H. et al. Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 2006; 29: 853-857
- 7 Erdmann J, Salmhofer H, Knauss A. et al. Relationship of fetuin-A levels to weight-dependent insulin resistance and type 2 diabetes mellitus. Regul Peptides 2012; 178: 6-10
- 8 Ishibashi A, Ikeda Y, Ohguro T. et al. Serum fetuin-A is an independent marker of insulin resistance in Japanese men. J Atheroscler Thromb 2010; 17: 925-933
- 9 Mori K, Emoto M, Yokoyama H. et al. Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care 2006; 29: 468
- 10 Ou HY, Yang YC, Wu HT. et al. Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose. J Clin Endocrinol Metab 2012; 97: 4717-4723
- 11 Rottenkolber M, Ferrari U, Holland L. et al. The diabetes risk phenotype of young women with recent gestational diabetes. J Clin Endocrinol Metab 2015; 100: E910-E918
- 12 Sujana C, Huth C, Zierer A. et al. Association of fetuin-A with incident type 2 diabetes: results from the MONICA/KORA Augsburg study and a systematic meta-Analysis. Eur J Endocrinol 2018; 178: 389-398
- 13 Stefan N, Sun Q, Fritsche A. et al. Impact of the adipokine adiponectin and the hepatokine fetuin-A on the development of type 2 diabetes: Prospective cohort- and cross-sectional phenotyping studies. PLoS One 2014; 9: e92238
- 14 Kroger J, Meidtner K, Stefan N. et al. Circulating fetuin-A and risk of type 2 diabetes: A mendelian randomization analysis. Diabetes 2018; 67: 1200-1205
- 15 Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470